Active Pharmaceutical Ingredients
- Industrial Coatings
- Dyes and Pigments
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
- Analytical Chemistry
- Pharmaceutical Intermediates
The novel coronavirus mRNA epidemic seedling CS-2034 (hereinafter referred to as "CS-2034"), jointly developed by CanSino Biologics Co.
(hereinafter referred to as the "Company") and its subsidiary CanSino (Shanghai) Biotechnology Co.
, has obtained positive phased data
in a clinical study evaluating sequential enhancement safety and immunogenicity.
CS-2034 is a protective mRNA vaccine of existing variants, and preclinical studies have shown that this vaccine can induce high-titer neutralizing antibodies against multiple WHO-recognized important variants, which is more broad-spectrum than the new coronavirus seedlings developed based on prototype strains, and can more effectively protect the body from infection by existing variants
Up to now, CS-2034 is still in the clinical phase IIb stage, and the current progress is in line with expectations, and the next stage of R&D will be planned
in the future according to the epidemic situation, national immunization strategy, review mechanism, etc.
, and based on the positive clinical data obtained.